ES2322455T3 - Uso de carnitinas para la prevencion y/o tratamiento de trastornos producidos por la andropausia. - Google Patents
Uso de carnitinas para la prevencion y/o tratamiento de trastornos producidos por la andropausia. Download PDFInfo
- Publication number
- ES2322455T3 ES2322455T3 ES03780642T ES03780642T ES2322455T3 ES 2322455 T3 ES2322455 T3 ES 2322455T3 ES 03780642 T ES03780642 T ES 03780642T ES 03780642 T ES03780642 T ES 03780642T ES 2322455 T3 ES2322455 T3 ES 2322455T3
- Authority
- ES
- Spain
- Prior art keywords
- carnitine
- propionyl
- acetyl
- acid
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- 230000002265 prevention Effects 0.000 title claims abstract description 7
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 42
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims abstract description 42
- 230000032683 aging Effects 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- -1 mucate Substances 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000035946 sexual desire Effects 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 206010012374 Depressed mood Diseases 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- BMTNDEZFXJLFGJ-UHFFFAOYSA-N [Mg].CCN Chemical compound [Mg].CCN BMTNDEZFXJLFGJ-UHFFFAOYSA-N 0.000 claims 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims 1
- 229940095060 magnesium tartrate Drugs 0.000 claims 1
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 105
- 229960003604 testosterone Drugs 0.000 description 52
- 229940068196 placebo Drugs 0.000 description 49
- 239000000902 placebo Substances 0.000 description 49
- 229960000746 testosterone undecanoate Drugs 0.000 description 19
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 230000009986 erectile function Effects 0.000 description 14
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 12
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000002307 prostate Anatomy 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 239000003098 androgen Substances 0.000 description 7
- 210000003899 penis Anatomy 0.000 description 7
- 102000003946 Prolactin Human genes 0.000 description 5
- 108010057464 Prolactin Proteins 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940097325 prolactin Drugs 0.000 description 5
- 238000009552 doppler ultrasonography Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000000422 nocturnal effect Effects 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000009165 androgen replacement therapy Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000017497 prostate disease Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000198676 Prunus cerasoides Species 0.000 description 1
- 235000009226 Prunus puddum Nutrition 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- MUZDLCBWNVUYIR-UHFFFAOYSA-L magnesium;2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)C(O)C(O)C([O-])=O MUZDLCBWNVUYIR-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM02A0620 | 2002-12-13 | ||
| IT000620A ITRM20020620A1 (it) | 2002-12-13 | 2002-12-13 | Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2322455T3 true ES2322455T3 (es) | 2009-06-22 |
Family
ID=32587900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03780642T Expired - Lifetime ES2322455T3 (es) | 2002-12-13 | 2003-11-20 | Uso de carnitinas para la prevencion y/o tratamiento de trastornos producidos por la andropausia. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7956091B2 (enExample) |
| EP (1) | EP1569635B1 (enExample) |
| JP (1) | JP4767542B2 (enExample) |
| KR (1) | KR101039818B1 (enExample) |
| AT (1) | ATE422883T1 (enExample) |
| AU (1) | AU2003288739A1 (enExample) |
| CA (1) | CA2507429C (enExample) |
| CY (1) | CY1109051T1 (enExample) |
| DE (1) | DE60326262D1 (enExample) |
| DK (1) | DK1569635T3 (enExample) |
| ES (1) | ES2322455T3 (enExample) |
| IT (1) | ITRM20020620A1 (enExample) |
| MX (1) | MXPA05006072A (enExample) |
| PL (1) | PL211032B1 (enExample) |
| PT (1) | PT1569635E (enExample) |
| SI (1) | SI1569635T1 (enExample) |
| WO (1) | WO2004054567A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272812A1 (en) * | 2002-02-07 | 2005-12-08 | Pettegrew Jay W | Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans |
| US7407778B2 (en) | 2002-02-07 | 2008-08-05 | Pettegrew Jay W | Compounds, compositions and methods for treating neuropsychiatric disorders |
| US7700074B2 (en) | 2002-02-07 | 2010-04-20 | Pettegrew Jay W | Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
| EP1641806B1 (en) | 2003-05-29 | 2009-07-29 | Jay W. Pettegrew | Glycerophosphocholine and its derivatives for medical imaging of neuropsychiatric disorders |
| ITRM20040561A1 (it) * | 2004-11-11 | 2005-02-11 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile. |
| KR101460125B1 (ko) * | 2013-02-05 | 2014-11-11 | 주식회사 바이오그랜드 | 루이보스 추출물을 유효성분으로 하는 남성 노화 및 갱년기 예방 및 개선용 조성물 |
| WO2016167254A1 (ja) * | 2015-04-17 | 2016-10-20 | 株式会社山田養蜂場本社 | 蜂の子を含有する滋養強壮剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3830931A (en) * | 1972-11-06 | 1974-08-20 | Felice S De | Carnitine and its use in the treatment of arrhythmia and impaired cardiac function |
| IT1206954B (it) * | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche |
| IT1116037B (it) * | 1979-04-23 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico |
| IT1157238B (it) * | 1982-10-29 | 1987-02-11 | Sigma Tau Ind Farmaceuti | Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile |
| EP0681839A3 (en) | 1994-05-12 | 1997-11-12 | Hirohiko Kuratsune | A pharmaceutical preparation comprising an acylcarnitine |
| IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
| IT1291127B1 (it) * | 1997-04-01 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica |
| IT1295408B1 (it) * | 1997-10-03 | 1999-05-12 | Sigma Tau Ind Farmaceuti | Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo |
| IT1302125B1 (it) * | 1998-08-03 | 2000-07-31 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide |
| IT1302307B1 (it) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
| IT1306130B1 (it) * | 1999-04-16 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti. |
| US6399116B1 (en) * | 2000-04-28 | 2002-06-04 | Rulin Xiu | Rhodiola and used thereof |
| DE60216090T2 (de) * | 2001-05-29 | 2007-05-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia |
-
2002
- 2002-12-13 IT IT000620A patent/ITRM20020620A1/it unknown
-
2003
- 2003-11-20 WO PCT/IT2003/000757 patent/WO2004054567A1/en not_active Ceased
- 2003-11-20 AU AU2003288739A patent/AU2003288739A1/en not_active Abandoned
- 2003-11-20 US US10/535,509 patent/US7956091B2/en not_active Expired - Lifetime
- 2003-11-20 SI SI200331543T patent/SI1569635T1/sl unknown
- 2003-11-20 EP EP03780642A patent/EP1569635B1/en not_active Expired - Lifetime
- 2003-11-20 ES ES03780642T patent/ES2322455T3/es not_active Expired - Lifetime
- 2003-11-20 DK DK03780642T patent/DK1569635T3/da active
- 2003-11-20 KR KR1020057009768A patent/KR101039818B1/ko not_active Expired - Fee Related
- 2003-11-20 AT AT03780642T patent/ATE422883T1/de active
- 2003-11-20 DE DE60326262T patent/DE60326262D1/de not_active Expired - Lifetime
- 2003-11-20 MX MXPA05006072A patent/MXPA05006072A/es active IP Right Grant
- 2003-11-20 JP JP2004560181A patent/JP4767542B2/ja not_active Expired - Fee Related
- 2003-11-20 PL PL378418A patent/PL211032B1/pl unknown
- 2003-11-20 PT PT03780642T patent/PT1569635E/pt unknown
- 2003-11-20 CA CA2507429A patent/CA2507429C/en not_active Expired - Lifetime
-
2009
- 2009-05-07 CY CY20091100492T patent/CY1109051T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1569635E (pt) | 2009-05-11 |
| JP2006511531A (ja) | 2006-04-06 |
| MXPA05006072A (es) | 2005-09-30 |
| US20060135606A1 (en) | 2006-06-22 |
| CA2507429C (en) | 2012-09-04 |
| KR20050084052A (ko) | 2005-08-26 |
| ITRM20020620A1 (it) | 2004-06-14 |
| DK1569635T3 (da) | 2009-04-20 |
| CA2507429A1 (en) | 2004-07-01 |
| EP1569635A1 (en) | 2005-09-07 |
| EP1569635B1 (en) | 2009-02-18 |
| ATE422883T1 (de) | 2009-03-15 |
| AU2003288739A1 (en) | 2004-07-09 |
| SI1569635T1 (sl) | 2009-06-30 |
| WO2004054567A1 (en) | 2004-07-01 |
| PL211032B1 (pl) | 2012-04-30 |
| US7956091B2 (en) | 2011-06-07 |
| JP4767542B2 (ja) | 2011-09-07 |
| PL378418A1 (pl) | 2006-04-03 |
| KR101039818B1 (ko) | 2011-06-09 |
| DE60326262D1 (de) | 2009-04-02 |
| CY1109051T1 (el) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2956148A1 (en) | Compositions and methods for pain relief without numbness | |
| ES2322455T3 (es) | Uso de carnitinas para la prevencion y/o tratamiento de trastornos producidos por la andropausia. | |
| US8435963B2 (en) | Weight loss compositions and uses thereof | |
| EP3107551A1 (en) | Compositions and methods for pain relief without numbness | |
| US7776913B2 (en) | Carnitines for treating or preventing disorders caused by andropause | |
| US20080161604A1 (en) | Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy | |
| JPH0657654B2 (ja) | 患者の疲労減少用組成物 | |
| PT1909782E (pt) | Composições que compreendem arginina e ácido r-alfa-lipóico e sua utilização para melhoramento da função sexual | |
| RU2113805C1 (ru) | Пищевая добавка янтавит | |
| US8952059B2 (en) | Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes | |
| ES2339265T3 (es) | Uso de acetil l-carnitina en combinacion con propionil l-carnitina y sildenafil para el tratamiento de la difuncion erectil. | |
| JP2014508740A (ja) | 治療用冷却剤組成物における溶媒としての使用のための（ｒ）−１，２−プロパンジオール | |
| ES2320788T3 (es) | Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico. | |
| US20230149330A1 (en) | Sleep quality improver | |
| ES2261772T3 (es) | Uso de la propionil l-carnitina o de una de sus sales farmacologicamente aceptables para la preparacion de una medicina para el tratamiento de la enfermedad de la peyronie. | |
| TWI735658B (zh) | 用於減少代謝症候群之組合物及其應用 | |
| US20250120425A1 (en) | Combinations of Ketogenic Supplements for Rapid and Sustained Blood Ketone Levels in Dieters and Patients | |
| RU2336878C2 (ru) | Средство для лечения эректильной дисфункции | |
| KR20140037045A (ko) | 치료적 쿨링제 조성물에서 용매로서 사용하기 위한 (r)-1,2-프로판디올 | |
| HK40083684A (en) | Agent for improving quality of sleep | |
| WO2006114372A1 (en) | Acetyl l-carnitine for preventing painful peripheral diabetic neuropathy | |
| WO2014163152A1 (ja) | ノンレム睡眠促進剤、深睡眠促進剤および自然睡眠誘発剤 |